<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461875</url>
  </required_header>
  <id_info>
    <org_study_id>Cabergoline / GnRH antagonist</org_study_id>
    <nct_id>NCT02461875</nct_id>
  </id_info>
  <brief_title>Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome</brief_title>
  <official_title>Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aljazeera Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aljazeera Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study is to compare the efficacy of GnRH antagonist rescue combined with
      cabergoline with cabergoline in the prevention of ovarian hyperstimulation syndrome in high
      risk patients undergoing ovarian stimulation for IVF-ET with long GnRH agonist protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of assisted
      reproduction. Complications of OHSS include vascular thrombosis, pulmonary embolism, renal
      failure, electrolyte disturbances, ascites, hydrothorax ,torsion of the ovary, abortion or
      rarely death.

      Previous studies revealed that converting a long GnRH agonist cycle to an GnRH antagonist
      cycle (GnRH antagonist rescue) reduced the risk of OHSS. Other studies revealed that
      cabergoline (potent dopamine receptor agonist on D2 receptors)was effective in preventing
      OHSS.

      The aim of study is to compare the efficacy of GnRH antagonist rescue combined with
      cabergoline with cabergoline in the prevention of ovarian hyperstimulation syndrome in high
      risk patients undergoing ovarian stimulation for IVF-ET with long GnRH agonist protocol.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moderate or severe ovarian hyperstimulation syndrome</measure>
    <time_frame>Within 4 weeks of HCG adminstration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Achieved Ongoing Pregnancy</measure>
    <time_frame>18 weeks after embryo transfer</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>OHSS</condition>
  <arm_group>
    <arm_group_label>Cabergoline group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cabergoline is administered starting on the day of HCG administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH antagonist rescue &amp; cabergoline group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Converting a long GnRH agonist cycle to an GnRH antagonist cycle (GnRH antagonist rescue) and Cabergoline is administered starting on the day of HCG administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.</description>
    <arm_group_label>Cabergoline group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist rescue &amp; cabergoline</intervention_name>
    <description>when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.</description>
    <arm_group_label>GnRH antagonist rescue &amp; cabergoline group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing ovarian stimulation for IVF-ET with long GnRH agonist protocol and
             at high risk of developing OHSS [ have more than 20 follicles ( 90% of them less than
             14 mm in mean diameter) and serum estradiol â‰¥ 3000 pg/ml]

        Exclusion Criteria:

          -  Fibrosis of lung,

          -  swelling or inflammation around the heart or lung,

          -  hypertension,

          -  liver disease,

          -  heart valve disease and

          -  allergy to cabergoline or ergot derivatives.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Usama M Fouda, M.D,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Aljazeera (Al Gazeera) hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Usama M Fouda, M.D,PhD</last_name>
    <phone>01095401375</phone>
    <email>umfrfouda@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aljazeera( Al Gazeera) hospital</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usama M. Fouda, M.D , PhD</last_name>
      <phone>01095401375</phone>
      <phone_ext>+2</phone_ext>
      <email>umfrfouda@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Usama M. Fouda, M.D , PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Aboulghar MA, Mansour RT, Amin YM, Al-Inany HG, Aboulghar MM, Serour GI. A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reprod Biomed Online. 2007 Sep;15(3):271-9.</citation>
    <PMID>17854523</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>November 15, 2015</last_update_submitted>
  <last_update_submitted_qc>November 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aljazeera Hospital</investigator_affiliation>
    <investigator_full_name>Prof .Usama M.Fouda</investigator_full_name>
    <investigator_title>M.D , PhD</investigator_title>
  </responsible_party>
  <keyword>OHSS</keyword>
  <keyword>Infertility</keyword>
  <keyword>Cabergoline</keyword>
  <keyword>GnRH antagonist</keyword>
  <keyword>IVF-ET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

